Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1

被引：0

作者：

Suvannasankha, Attaya ^{[1
,2
]}

Lee, Hans ^{[3
]}

Bumma, Naresh ^{[4
]}

Dhodapkar, Madhav V. ^{[5
]}

Richter, Joshua ^{[6
]}

Hoffman, James E. ^{[7
]}

Shah, Mansi ^{[8
]}

Lentzsch, Suzanne ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Maly, Joseph J. ^{[12
]}

Namburi, Swathi ^{[13
]}

Wu, Ka Lung ^{[14
]}

Pianko, Matthew ^{[15
]}

Silbermann, Rebecca ^{[16
]}

Min, Chang-Ki ^{[17
]}

Vekemans, Marie-Christiane ^{[18
]}

Munder, Markus ^{[19
]}

Martinez Lopez, Joaquin ^{[20
]}

DeVeaux, Michelle ^{[21
]}

Chokshi, Dhruti ^{[21
]}

Boyapati, Anita ^{[21
]}

Kroog, Glenn S. ^{[21
]}

Houvras, Yariv ^{[21
]}

Jagannath, Sundar ^{[22
]}

机构：

[1] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA

[2] Roudebush VAMC, Indianapolis, IN USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[5] Emory Univ, Sch Med, Atlanta, GA USA

[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[7] Univ Miami Hlth Syst, Miami, FL 33125 USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI 48201 USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] Norton Canc Inst, Louisville, KY USA

[13] Swedish Canc Inst, Seattle, WA USA

[14] ZNA Cadix, Antwerp, Belgium

[15] Univ Michigan Hlth, Rogel Canc Ctr, Ann Arbor, MI USA

[16] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[17] Catholic Univ Korea, St Marys Hosp, Seoul, South Korea

[18] Univ Catholic Louvain UCLouvain, Clin Univ St Luc, Dept Hematol, Brussels, Belgium

[19] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[20] Univ Complutense, Hosp 12 Octubre, CNIO, Sch Med ,i 12, Madrid, Spain

[21] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[22] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-084

引用

页码：S90 / S91

页数：2

共 50 条

[21] DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
Lokhorst, H.
Laubach, J.
Nahi, H.
Plesner, T.
Gimsing, P.
Hansson, M.
Minnema, M.
Lassen, U.
Krejcik, J.
Ahmadi, T.
Khan, I.
Uhlar, C.
Lisby, S.
Basse, L.
Brun, N.
Richardson, P.
HAEMATOLOGICA, 2014, 99 : 106 - 107
[22] Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)
Jakubowiak, Andrzej J.
Richardson, Paul G.
Zimmerman, Todd M.
Alsina, Melissa
Kaufman, Jonathan L.
Kandarpa, Malathi
Harvey, Colleen K.
Colson, Kathleen
Mitchell, Monica
Hideshima, Teru
Sportelli, Peter
Gardner, Lesa
Giusti, Kathy
Anderson, Kenneth C.
BLOOD, 2010, 116 (21) : 1264 - 1264
[23] Bortezomib in relapsed or refractory multiple myeloma:: results in a cohort of 39 patients
Canovas Fernandez, A.
Alonso Alonso, J. J.
Barreiro Garcia, J. G.
Aguirre Errasti, C.
REVISTA CLINICA ESPANOLA, 2008, 208 (04): : 187 - 192
[24] TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
Abu-Rashed, Esraa
Sharif, Joseph
Rocci, Alberto
TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S363 - S365
[25] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Szatrowski, T.
Kaplita, S.
Anderson, K. C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
[26] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
Kyrtsonis, MC
Sachanas, S
Vassilakopoulos, TP
Kafassi, N
Tzenou, T
Papadogiannis, A
Kalpadakis, C
Antoniadis, AG
Dimopoulou, MN
Angelopoulou, MK
Siakantaris, MP
Dimitriadou, EM
Kokoris, SI
Plata, E
Tsaftaridis, P
Panayiotidis, P
Pangalis, GA
BLOOD, 2005, 106 (11) : 382B - 382B
[27] Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial.
Richardson, PG
Chanan-Khan, AA
Alsina, M
Doss, D
Landrigan, B
Kettner, D
Albitar, M
Mitsiades, C
Cropp, GF
Johnson, RG
Hannah, AL
Anderson, KC
BLOOD, 2005, 106 (11) : 109A - 109A
[28] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
Lacy, Martha Q.
LaPlant, Betsy R.
Laumann, Kristina M.
Kumar, Shaji
Gertz, Morie A.
Hayman, Suzanne R.
Buadi, Francis
Dispenzieri, Angela
Lust, John A.
Kapoor, Prashant
Leung, Nelson
Russell, Stephen J.
Dingli, David
Gonsalves, Wilson I.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Sher, Taimur
Ailawadhi, Sikander
Chanan-Khan, Asher
Stewart, A. Keith
Reeder, Craig B.
Rajkumar, S. Vincent
Mikhael, Joseph R.
BLOOD, 2014, 124 (21)
[29] Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
Jakubowiak, Andrzej
Wang, Luhua
Orlowski, Robert Z.
Jagannath, Sundar
Siegel, David
Stewart, A. Keith
Kukreti, Vishal
Lonial, Sagar
McDonagh, Kevin T.
Vallone, Marcy
Kauffman, Michael
Vij, Ravi
BLOOD, 2009, 114 (22) : 725 - 726
[30] Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
Damaj, G.
Malard, F.
Hulin, C.
Caillot, D.
Garidi, R.
Royer, B.
Marit, G.
Stoppa, A. M.
Banos, A.
Morineau, N.
Moreau, P.
Fitoussi, O.
Tiab, M.
Moreau, P.
LEUKEMIA & LYMPHOMA, 2012, 53 (04) : 632 - 634

← 1 2 3 4 5 →